Estimation of galectin-3 level in female patients with chronic heart failure, type 2 diabetes mellitus, and asymptomatic hyperuricemia

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Significant prevalence and often chronic heart failure (CHF) late diagnosing in patients with comorbid pathology, including type 2 diabetes mellitus (T2DM) and hyperuricemia, and high mortality rate in this group of patients dictate the need to search for new prognostic biomarkers.

The aim: to assess galectin-3 levels and the clinical course of CHF in patients with T2DM and asymptomatic hyperuricemia (AHU).

Material and methods. Uric acid and galectin-3 levels, as well as clinical characteristics of the clinical course of the disease, were estimated in 128 patients with CHF. Depending on the presence of T2DM and AHU, the study participants were divided into 4 groups: group 1: CHF + T2DM + AHU (n = 33); group 2: CHF + T2DM (n = 35); group 3: CHF + AHU (n = 36); group 4 – CHF without T2DM and AHU (n = 24).

Results. Patients with diabetes and glomerular filtration rate (GFR) had statistically significantly (p <0.05) higher levels of uric acid, natriuretic peptide (NT-proBNP), and glomerular filtration rate (GFR), as well as a higher probability of developing retinopathy, neuropathy, and angina pectoris. Moreover, these patients also had higher levels of galectin-3 (p <0.05). Furthermore, the presence of glomerular filtration rate (GFR) alone in combination with CHF increased the risk of developing more severe kidney damage (as was measured by GFR), while the presence of diabetes alone increased the risk of developing cardiac damage (according to NT-proBNP level) (p <0.05). Spearman’s rank correlation analysis revealed the following significant correlations: a high-confidence direct correlation between NT-proBNP and galectin-3 (ρху = 0.837, p < 0.001), markedly tight inverse correlation between left ventricular ejection fraction and NT-proBNP levels (ρху = -0.654, p <0.001), and between left ventricular ejection fraction and galectin-3 levels (ρху = -0.515, p <0.001), also moderate-confidence direct correlation between uric acid level and galectin-3 (ρху = 0.469, p <0.01), and moderate-confidence inverse correlation between uric acid level and GFR (ρху = -0.474, p <0.01).

Conclusion. Estimation of galectin-3 level may help predict the risk of cardiovascular diseases associated with AHU in the presence of T2DM, as well as their complications.

全文:

受限制的访问

作者简介

Marina Kolpacheva

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: marina.kolpacheva.1997@mail.ru
ORCID iD: 0009-0000-4851-9766
SPIN 代码: 8381-0600

MD, assistant at the Department of outpatient therapy

俄罗斯联邦, Voronezh

Anna Pashkova

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

Email: apashkova@vrngmu.ru
ORCID iD: 0009-0002-9026-7763
SPIN 代码: 7605-1630

MD, Dr. Sci. (Medicine), professor, head of the Department of outpatient therapy

俄罗斯联邦, Voronezh

Lyubov Antakova

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

Email: tsvn@bk.ru
ORCID iD: 0000-0001-5212-1005
SPIN 代码: 3936-3381

PhD (Biol. Sci.), senior researcher, head of the Department of postgenomic research of the Research Institute of Experimental Biology and Medicine

俄罗斯联邦, Voronezh

Olga Gerasimova

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

Email: stavro7@mail.ru
ORCID iD: 0000-0001-8662-5279
SPIN 代码: 3509-3856

PhD (Biol. Sci.), senior researcher at the Research Institute of Experimental Biology and Medicine

俄罗斯联邦, Voronezh

Elena Alferova

Voronezh City Clinical Emergency Hospital No. 1

Email: elna_y@mail.ru
ORCID iD: 0009-0001-5729-4877

MD, PhD (Medicine), head of the 2nd Department of cardiology, cardiologist of the highest category

俄罗斯联邦, Voronezh

参考

  1. Шляхто Е.В., Беленков Ю.Н., Бойцов С.А., Виллевальде С.В., Галявич А.С., Глезер М.Г. с соавт. Проспективное наблюдательное многоцентровое регистровое исследование пациентов с хронической сердечной недостаточностью в Российской Федерации (ПРИОРИТЕТ-ХСН): обоснование, цели и дизайн исследования. Российский кардиологический журнал. 2023;28(6):7–14. [Shlyakhto EV, Belenkov YuN, Boytsov SA, Villevalde SV, Galyavich AS, Glezer MG et al. Prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation (PRIORITY-CHF): Rationale, objectives and design of the study. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023;28(6):7–14 (In Russ.)]. EDN: LKSHVP. https://doi.org/10.15829/1560-4071-2023-5456
  2. Heidenreich P. Heart failure management guidelines: New recommendations and implementation. J Cardiol. 2024;83(2):67–73. PMID: 37949313. https://doi.org/10.1016/j.jjcc.2023.10.009
  3. Vaz-Salvador P, Adao R, Vasconcelos I, Leite-Moreira AF, Bras-Silva C. Heart failure with preserved ejection fraction: A pharmacotherapeutic update. Cardiovasc Drugs Ther. 2023;37(4):815–32. PMID: 35098432. PMCID: PMC8801287. https://doi.org/10.1007/s10557-021-07306-8
  4. Колпачева М.Г., Пашкова А.А., Шевцова В.И. Влияние гиперурикемии и сахарного диабета 2-го типа на развитие и течение хронической сердечной недостаточности. Лечащий врач. 2025;28(3):29–33. [Kolpacheva MG, Pashkova AA, Shevtsova VI. The influence of hyperuricemia and type 2 diabetes mellitus on the development and course of chronic heart failure. Lechashchiy vrach = Attending Physician. 2025;28(3):29–33 (In Russ.)]. EDN: PHKEYX. https://doi.org/10.51793/OS.2025.28.3.004
  5. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121–41. PMID: 30605420. PMCID: PMC6447311. https://doi.org/10.1161/CIRCRESAHA.118.311371
  6. Deng Y, Liu F, Yang X, Xia Y. The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation. Front Cardiovasc Med. 2021;8:641136. PMID: 33718459; PMCID: PMC7952317. https://doi.org/10.3389/fcvm.2021.641136
  7. Newlaczyl AU, Yu LG. Galectin-3 – a jack-of-all-trades in cancer. Cancer Lett. 2011;313(2):123–28. PMID: 21974805. https://doi.org/10.1016/j.canlet.2011.09.003
  8. Verkerke H, Dias-Baruffi M, Cummings RD, Arthur CM, Stowell SR. Galectins: An ancient family of carbohydrate binding proteins with modern functions. Methods Mol Biol. 2022;2442:1–40. PMID: 35320517. https://doi.org/10.1007/978-1-0716-2055-7_1
  9. Zhong X, Qian X, Chen G, Song X. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197–203. PMID: 30372548. https://doi.org/10.1111/1440-1681.13048
  10. Shaukat Sid, Nadeem A, Mazloom F, Rameez R, Shaukat Sad. Correlation of serum galectin-3 levels with ejection fractions in healthy subjects and heart failure patients. Pak J Physiol. 2022;18(2):28–30. https://doi.org/10.69656/pjp.v18i2.1427
  11. Sygitowicz G, Maciejak-Jastrzebska A, Sitkiewicz D. The diagnostic and therapeutic potential of galectin-3 in cardiovascular diseases. Biomolecules. 2022;12(1):46. PMID: 35053194. PMCID: PMC8774137. https://doi.org/10.3390/biom12010046
  12. Rafiullah M, Siddiqui K, Al-Rubeaan K. Association between serum uric acid levels and metabolic markers in patients with type 2 diabetes from a community with high diabetes prevalence. Int J Clin Pract. 2020;74(4):e13466. PMID: 31854061. https://doi.org/10.1111/ijcp.13466
  13. Khadeja Bi A, Santhosh V, Sigamani K. Levels of galectin-3 in chronic heart failure: A case-control study. Cureus. 2022;14(8):e28310. PMID: 36158385. PMCID: PMC9499328. https://doi.org/10.7759/cureus.28310
  14. Zaborska B, Sikora-Frac M, Smarz K, Pilichowska-Paszkiet E, Budaj A, Sitkiewicz D, Sygitowicz G. The role of galectin-3 in heart failure-the diagnostic, prognostic and therapeutic potential – where do we stand? Int J Mol Sci. 2023;24(17):13111. PMID: 37685918. PMCID: PMC10488150. https://doi.org/10.3390/ijms241713111
  15. Khan S, Ahmad SS, Kamal MA. Diabetic cardiomyopathy: From mechanism to management in a nutshell. Endocr Metab Immune Disord Drug Targets. 2021;21(2):268–81. PMID: 32735531. https://doi.org/10.2174/1871530320666200731174724
  16. Schmitt VH, Prochaska JH, Foll AS, Schulz A, Keller K, Hahad O et al. Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus. Sci Rep. 2021;11(1):19012. PMID: 34561496. PMCID: PMC8463561. https://doi.org/10.1038/s41598-021-98227-x
  17. Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A et al.; the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020;75(2):302–8. PMID: 31813345. https://doi.org/10.1161/HYPERTENSIONAHA.119.13643
  18. Waheed Y, Yang F, Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med. 2021;36(6):1281–93. PMID: 33045808. PMCID: PMC8588983. https://doi.org/10.3904/kjim.2020.340
  19. Vijay K, Neuen BL, Lerma EV. Heart failure in patients with diabetes and chronic kidney disease: Challenges and opportunities. Cardiorenal Med. 2022;12(1):1–10. PMID: 34802000. https://doi.org/10.1159/000520909
  20. Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and progression of chronic kidney disease: A review from physiology and pathogenesis to the role of urate-lowering therapy. Diagnostics (Basel). 2021;11(9):1674. PMID: 34574015. PMCID: PMC8466342. https://doi.org/10.3390/diagnostics11091674
  21. Barman Z, Hasan M, Miah R, Mou AD, Hafsa JM, Trisha AD et al. Association between hyperuricemia and chronic kidney disease: A cross-sectional study in Bangladeshi adults. BMC Endocr Disord. 2023;23(1):45. PMID: 36803682. PMCID: PMC9942427. https://doi.org/10.1186/s12902-023-01304-7

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. The results of the evaluation of the left ventricular ejection fraction in various study groups

下载 (39KB)
索引源数据
3. Fig. 2. Galectin-3 levels in different study groups

下载 (29KB)
索引源数据

版权所有 © Bionika Media, 2025